Literature DB >> 30696619

Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.

Gaurav Goyal1, Denise Lau2, Alison M Nagle2, Robert Vassallo3, Karen L Rech4, Jay H Ryu3, Caroline J Davidge-Pitts5, W Oliver Tobin6, Matthew J Koster7, N Nora Bennani1, Mithun V Shah1, Minetta C Liu3,8, Ronald S Go1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30696619      PMCID： PMC6911819          DOI： 10.1182/blood-2018-12-893917

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  19 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes.

Authors:  Gaurav Goyal; Mithun V Shah; Christopher C Hook; Alexandra P Wolanskyj; Timothy G Call; Karen L Rech; Ronald S Go
Journal:  Br J Haematol       Date:  2017-06-27       Impact factor: 6.998

4.  Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.

Authors:  Sofia Garces; L Jeffrey Medeiros; Keyur P Patel; Shaoying Li; Sergio Pina-Oviedo; Jingyi Li; Juan C Garces; Joseph D Khoury; C Cameron Yin
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

5.  Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort.

Authors:  Fleur Cohen-Aubart; Jean-François Emile; Fabrice Carrat; Zofia Helias-Rodzewicz; Valérie Taly; Frédéric Charlotte; Philippe Cluzel; Jean Donadieu; Ahmed Idbaih; Stéphane Barete; Zahir Amoura; Julien Haroche
Journal:  Am J Hematol       Date:  2018-02-10       Impact factor: 10.047

Review 6.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.

Authors:  Sandip Pravin Patel; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2015-02-18       Impact factor: 6.261

7.  Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.

Authors:  Shree Bose; Joanna Robles; Chad M McCall; Anand S Lagoo; Daniel S Wechsler; Gary R Schooler; David Van Mater
Journal:  Pediatr Blood Cancer       Date:  2018-09-30       Impact factor: 3.167

8.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Authors:  Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

9.  Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Authors:  Eli L Diamond; Vivek Subbiah; A Craig Lockhart; Jean-Yves Blay; Igor Puzanov; Ian Chau; Noopur S Raje; Jurgen Wolf; Joseph P Erinjeri; Jean Torrisi; Mario Lacouture; Elena Elez; Ferran Martínez-Valle; Benjamin Durham; Maria E Arcila; Gary Ulaner; Omar Abdel-Wahab; Bethany Pitcher; Martina Makrutzki; Todd Riehl; José Baselga; David M Hyman
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

10.  Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.

Authors:  Zoran Gatalica; Nurija Bilalovic; Juan P Palazzo; Ryan P Bender; Jeffrey Swensen; Sherri Z Millis; Semir Vranic; Daniel Von Hoff; Robert J Arceci
Journal:  Oncotarget       Date:  2015-08-14
View more
  8 in total

Review 1.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

2.  A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab.

Authors:  Yu Furui; Takashi Kurata; Kazutoshi Komori; Eriko Uchida; Yosuke Miyairi; Akihiro Chiba; Yoshifumi Ogiso; Kazuo Sakashita
Journal:  Int Cancer Conf J       Date:  2022-06-30

Review 3.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16

4.  Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Authors:  Gaurav Goyal; Aishwarya Ravindran; Jason R Young; Mithun V Shah; N Nora Bennani; Mrinal M Patnaik; Grzegorz S Nowakowski; Gita Thanarajasingam; Thomas M Habermann; Robert Vassallo; Taimur Sher; Sameer A Parikh; Karen L Rech; Ronald S Go
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

5.  PD-1/PD-L1 expression is frequent and correlated with lymphocyte density in Erdheim-Chester disease.

Authors:  Frederic Charlotte; Fleur Cohen-Aubart; Levi-Dan Azoulay; Zahir Amoura; Jean-Francois Emile; Julien Haroche
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047

6.  Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.

Authors:  Jia Chen; Sheng Wei; Tianye Zhao; Xunlei Zhang; Yilang Wang; Xiaodong Zhang
Journal:  Dis Markers       Date:  2022-07-30       Impact factor: 3.464

7.  Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma.

Authors:  Saurabh Zanwar; Aishwarya Ravindran; Jithma P Abeykoon; Jason R Young; Timothy F Kozelsky; Karen L Rech; Gaurav Goyal; Ronald S Go
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

Review 8.  Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: A case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations.

Authors:  Nelson Montalvo; Jorge Lara-Endara; Ligia Redrobán; María Leiva; Christian Armijos; Leonardo Russo
Journal:  Cancer Rep (Hoboken)       Date:  2021-07-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.